Drug makers race to release drugs that fight blood clots

NEW YORK Johnson & Johnson, Bayer and Boehringer Ingelheim may rake in huge profits with novel drugs for fighting blood clots, according to Bloomberg News.

Research data reported at the annual meeting of the American Society of Hematology in San Francisco found that the new drugs were more effective than Bristol-Myers Squibb’s Coumadin (warfarin). They include Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and Xarelto (rivaroxaban), made by Bayer and J&J.